Her current research has two areas of focus. First, she has a clinical opioid research program with the overarching goal of developing and evaluating more efficacious treatments for opioid dependence. She also has longstanding research interest aimed at leveraging behavioral economic principles to support healthy behaviors, especially among disadvantaged populations. Most recently, this has involved tackling cigarette smoking among the challenging population of opioid-dependent patients. Dr. Sigmon is the director of Vermont’s first and largest opioid treatment program, which currently delivers methadone or buprenorphine maintenance treatment to approximately 1,000 Vermonters. Go Back